Opinion|Videos|December 27, 2024
Navigating Recovery: CAR-T Cell Therapy Experience
Panelists discuss how patients’ lives change after receiving chimeric antigen receptor (CAR) T-cell therapy, comparing the recovery process to previous lines of therapy, and how overall quality of life improves or changes following CAR T-cell treatment.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How has your life changed since receiving chimeric antigen receptor (CAR) T-cell therapy?
- How would you compare the recovery process with your experience after your previous lines of therapy?
- How has your overall quality of life improved or changed compared with before CAR T-cell therapy?
Advertisement
Related to this article
Jeffrey V. Matous, MD, explains why ramantamig’s MRD negativity rates are clinically significant in relapsed/refractory myeloma.
In the phase 2 RALLY-MF study, selcodebart produced a 55% major response rate among evaluable non–transfusion-dependent patients with myelofibrosis.
Experts in multiple myeloma discussed long-term MAIA and CEPHEUS trial data and their implications for daratumumab-based regimens in newly diagnosed disease.
Adjuvant radiotherapy significantly reduced meningioma recurrence or death vs observation in grade 2 atypical meningioma after complete surgical resection.
VIR-5500, a PSMA-targeted PRO-XTEN dual-masked T-cell engager, showed an 82% PSA50 response rate and 45% ORR at higher doses in heavily pretreated mCRPC.
Experts discuss why the convenience of the all-oral decitabine/cedazuridine plus venetoclax regimen does not reduce the need for close monitoring in AML.
Ravi Patel, MD, PhD, discusses expanding theranostics access, personalized dosing strategies, and translational research in radiation oncology.
Jeffrey V. Matous, MD, discusses how to counsel patients on chronic, low-grade toxicities to support adherence to ramantamig.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Atezolizumab/Chemo for Stage III dMMR Colon Cancer
2
Building out a Radiopharmaceuticals Program in Oncology Care
3
Iberdomide Combination Doubles PFS vs SOC Therapy in R/R Multiple Myeloma
4
How Would a TALAPRO-3 Approval Affect HRR-Altered Metastatic HSPC Care?
5